Accuracy and Reliability of Novii: Fetal Heart Rate (FHR), Maternal Heart Rate (MHR) and Uterine Contraction (UA) Compared With Doppler, Scalp Fetal Scalp Electrode (FSE), Tocodynamometer (TOCO) and Intra Uterine Pressure Catheter (IUPC)
Accuracy and Reliability of a New Intrapartum Fetal Heart Rate, Maternal Heart Rate, and Uterine Contraction Monitoring Method Compared With Food and Drug Administration (FDA) Approved Techniques.
1 other identifier
observational
80
1 country
1
Brief Summary
Accuracy and Reliability of the Novii device (fetal heart rate, maternal heart rate and uterine activity) compared with Food and Drug Administration (FDA) approved techniques
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2014
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 28, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 13, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
February 13, 2017
CompletedFirst Submitted
Initial submission to the registry
January 11, 2018
CompletedFirst Posted
Study publicly available on registry
January 24, 2018
CompletedFebruary 9, 2021
February 1, 2021
2.7 years
January 11, 2018
February 4, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Fetal Heart Rate (FHR) Positive Percentage Agreement (PPA)
PPA(%)=(a/(a+C))x100, where "a" represents the number of 2 second epochs when the Novii FHR is within +/-10% of the predicate device FHR for each 2 second epoch, and "c" are the number of 2 second epochs when the Novii FHR is not within +/- 10% of the predicate device FHR or is absent.
through study completion, an average of 1 year
Secondary Outcomes (5)
Mean Percentage FHR Equivalence
through study completion, an average of 1 year
Uterine Activity (UA) Sensitivity (from Individual Contractions)
through study completion, an average of 1 year
Uterine activity Positive Percentage Agreement (from Interpretable Data)
through study completion, an average of 1 year
Maternal Heart Rate (MHR) Positive Percentage Agreement (PPA)
through study completion, an average of 1 year
Mean Percentage MHR Equivalence
through study completion, an average of 1 year
Study Arms (1)
Term Patients
Approximately 80 pregnant women monitored in labor between 37 and 42 weeks' gestation will be necessary to complete the study. Subjects will have a singleton \>37 week pregnancy. Subjects will be recruited for the study in the following groups : At least 10 patients with Body Mass Index (BMI) \< 30 kg/m2 At least 10 patients with BMI 30-34.9 kg/m2 At least 10 patients with BMI ≥ 35 kg/m2
Interventions
The Monica Novii Wireless Patch System is a transabdominal fetal/maternal recorder that provides fetal heart rate, maternal heart rate and maternal uterine activity contractions.
Eligibility Criteria
Pregnant Women at Term
You may qualify if:
- She has a term or near term (≥36 completed weeks) singleton gestation in a cephalic presentation and has been admitted to the Labor and Delivery Unit .
- She is in the latent phase of spontaneous labor, or has been admitted for induction of labor.
- She has given her informed consent to participate as a subject.
You may not qualify if:
- Known major fetal malformation or chromosome abnormality.
- Multiple gestation
- A condition for which cesarean will likely be carried out shortly.
- Subject plans not to have electronic fetal monitoring.
- Involvement in another clinical trial currently or previously in this pregnancy that, in the investigator's opinion, would affect the conduct of this study.
- Medical or obstetric problem that would preclude the use of abdominal electrodes (e.g., skin eruptions, history of sensitivity to adhesives).
- Parturient is under age 18.
- Medical or obstetric problem that in investigator's opinion would make the patient incapable of taking part in the study.
- Inability to understand the consent information due to medical illness or diminished intellectual capacity, or insurmountable language barrier.
- Potential for coercion, e.g. Medical Center employees, prisoners.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- GE Healthcarelead
Study Sites (1)
University of Arizona Medical Center
Tucson, Arizona, 85724, United States
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 11, 2018
First Posted
January 24, 2018
Study Start
May 28, 2014
Primary Completion
February 13, 2017
Study Completion
February 13, 2017
Last Updated
February 9, 2021
Record last verified: 2021-02
Data Sharing
- IPD Sharing
- Will not share